Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder

American Journal of Psychiatry

Volumn 154, Issue 8, 1997, Pages 1057-1062

  Sallee, Floyd R ^a,b   Nesbitt, Lori ^a   Jackson, Cherry ^a   Sine, Lauren ^a   Sethuraman, Gopalan ^a  

^a Institute of Psychiatry   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PIMOZIDE;

ADOLESCENT; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TITRIMETRY;

EID: 0030872372     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.8.1057     Document Type: Article

References (29)

1. Singer HS, Walkup JT: Tourette syndrome and other tic disorders: diagnosis, pathophysiology, and treatment. Medicine 1991; 70:15-32
2. Apter A, Pauls DL, Bleich A, Zohar AH, Kron S, Ratzoni G, Dycian A, Kotler M, Weizman A, Gadot N, Cohen DJ: An epidemiologic study of Gilles de la Tourette's syndrome in Israel. Arch Gen Psychiatry 1993; 50:734-738
3. Erenberg G, Cruse RP, Rothner AD: The natural history of Tourette's syndrome: a follow-up study. Ann Neurol 1987; 22:383-385
4. Chappell PB, Leckman JF, Riddle MA: The pharmacologic treatment of tic disorders. Child and Adololescent Psychiatr Clin North Am 1995; 4:197-216
5. Richardson MA, Haugland G, Craig TJ: Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 1991; 148:1322-1328
6. Bruun RD: Subtle and underecognized side effects of neuroleptic treatment in children with Tourette's disorder. Am J Psychiatry 1988; 145:621-624
7. Ross MS, Moldofsky H: A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am J Psychiatry 1978; 135:585-587
8. Shapiro AK, Shapiro E, Eisenkraft GJ: Treatment of Gilles de la Tourette syndrome with pimozide. Am J Psychiatry 1983; 140: 1183-1186
9. Walters JR, Roth RH: Dopaminergic neurons: alteration in the sensitivity of tyrosine hydroxylase to inhibition by endovenous dopamine after cessation of impulse flow. Biochem Pharmacol 1976; 25:649-654
10. Tecott LH, Kwong LL, Uhr S, Peroutka SJ: Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine, and pimozide. Biol Psychiatry 1986; 21:1114-1122
11. Messiha FS: Genetics, haloperidol and pimozide: a comparative study in two mouse strains. Neurotoxicology 1991; 12:47-54
12. Blandina P, Goldfarb J, Craddock-Royal B, Green JP: Release of endogenous dopamine by stimulation of 5-hydroxytryptamine receptors in rat striatum. J Pharmacol Exp Ther 1989; 251:803-809
13. Sallee FR, Dougherty D, Sethuraman G, Vrindavanam N: Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Biol Psychiatry 1996; 40:1044-1050
14. Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, Phillips RA: Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989; 46:722-730
15. Chambers WJ, Puig-Antich J, Hirsch M: The assessment of affective disorders in children and adolescents by semistructured interview. Arch Gen Psychiatry 1985; 42:696-702
16. Harcherik DF, Leckman JF, Detlor J, Cohen DJ: A new instrument for clinical studies of Tourette's syndrome. J Am Acad Child Psychiatry 1984; 23:153-160
17. Walkup JT, Rosenberg LA, Brown J, Singer HS: The validity of instruments measuring tic severity in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1992; 31:472-477
18. Leckman JF, Towbin KE, Ort SI, Cohen DJ: Clinical assessment of tic disorder severity, in Tourette's Syndrome and Tic Disorders. Edited by Cohen DJ. New York, John Wiley & Sons, 1988, pp 55-78
19. Shaffer D, Gould MS, Brasic JA: Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry 1983; 40:1228-1231
20. Guy W: ECDEU Assessment Manual for Psychopharmacology. Washington, DC, US Department of Health, Education, and Welfare, 1976
21. Chouinard G, Annable L, Ross-Chouinard A, Kropsky ML: Ethopropazine and benztropine in neuroleptic-induced parkinsonism. J Clin Psychiatry 1979; 40:147-152
22. Keuls M: The use of the Studentized range in connection with an analysis of variance. Euphytica 1952; 1:112-122
23. Zimmerman H, Rahlfs V: Testing hypotheses in the two-period change-over design with binary data. Biometrical Journal 1978; 20:133-141
24. Grizzle JE: The two-period change-over design and its use in clinical trials. Biometrics 1965; 21:467-480
25. Sallee FR, Pollock BG, Stiller RL, Stull S, Everett G, Perel JM: Pharmacokinetics of pimozide in adults and children with Tourette's syndrome. J Clin Pharmacol 1987; 27:776-781
26. Caine ED, Polinsky RJ: Haloperidol-induced dysphoria in patients with Tourette syndrome. Am J Psychiatry 1979; 136: 1216-1217
27. Mikkelsen EJ, Detlor J, Cohen DJ: School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder. Am J Psychiatry 1981; 138:1572-1576
28. Stefl ME: Mental health needs associated with Tourette syndrome. Am J Public Health 1984; 74:1310-1313
29. Silva R, Magee H, Friedhoff A: Persistent tardive dyskinesia and other neuroleptic-related dyskinesias in Tourette's disorder. J Child and Adolescent Psychopharmacology 1993; 3:137-144